Literature DB >> 11781305

Antiviral activity of interferon-alpha against hepatitis B virus can be studied in non-hepatic cells and Is independent of MxA.

Andreas Rang1, Michael Bruns, Tilman Heise, Hans Will.   

Abstract

It is well established that interferon-alpha can induce non-cytotoxic intracellular suppression of hepatitis B virus replication, but the mechanisms involved are unclear. Cell culture studies to characterize these mechanisms are restricted, in part because hepatitis B virus replicates almost exclusively in liver-derived cells. To overcome this limitation we used a cytomegalovirus promoter-controlled hepatitis B virus expression system, which leads to intracellular viral replication even in non-hepatic cell lines. In this experimental system interferon-alpha treatment specifically suppressed viral replication demonstrating that antiviral activities against hepatitis B virus are not restricted to hepatic cells. Furthermore, the interferon-inducible MxA protein was recently reported to play a key role in the antiviral action of interferon-alpha against hepatitis B virus. Our data demonstrate that interferon-alpha also suppresses hepatitis B virus replication in MxA-deficient HEp2 cells, indicating that MxA is not essential for these activities. Taken together, our data imply that the experimental approach presented can also be adapted to established cell lines which are deficient in parts of the signal transduction pathway or other elements located further downstream, providing important insights into mechanisms specifically suppressing hepatitis B virus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11781305     DOI: 10.1074/jbc.C100729200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs.

Authors:  Jianhua Li; Shanshan Lin; Qiying Chen; Lu Peng; Jianwei Zhai; Yinghui Liu; Zhenghong Yuan
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

2.  Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo.

Authors:  Melanie Fiedler; Florian Rödicker; Valentina Salucci; Mengji Lu; Luigi Aurisicchio; Uta Dahmen; Li Jun; Olaf Dirsch; Brigitte M Pützer; Fabio Palombo; Michael Roggendorf
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

3.  Hepatitis B virus core protein with hot-spot mutations inhibit MxA gene transcription but has no effect on inhibition of virus replication by interferon α.

Authors:  Yu Zhijian; Huang Zhen; Zhang Fan; Yang Jin; Deng Qiwen; Zeng Zhongming
Journal:  Virol J       Date:  2010-10-20       Impact factor: 4.099

4.  Cell-type specific interferon stimulated gene staining in liver underlies response to interferon therapy in chronic HBV infected patients.

Authors:  Yanling Zhu; Bo Qin; Chunyan Xiao; Xi Lu; Limin Chen
Journal:  Dig Dis Sci       Date:  2012-05-15       Impact factor: 3.199

5.  Searching for interferon-induced genes that inhibit hepatitis B virus replication in transgenic mouse hepatocytes.

Authors:  Stefan F Wieland; Raquel G Vega; Rolf Müller; Claire F Evans; Brian Hilbush; Luca G Guidotti; J Gregor Sutcliffe; Peter G Schultz; Francis V Chisari
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  ADAR1 Stimulation by IFN-α Downregulates the Expression of MAVS via RNA Editing to Regulate the Anti-HBV Response.

Authors:  Tao Li; Xiaoshuang Yang; Wei Li; Jiaru Song; Zhuo Li; Xilin Zhu; Xiaopan Wu; Ying Liu
Journal:  Mol Ther       Date:  2020-12-03       Impact factor: 11.454

Review 7.  The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs.

Authors:  Nidhi Gupta; Milky Goyal; Catherine H Wu; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2014-09-15

8.  Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy.

Authors:  Xu-Qing Zhang; Hui-Yan Zhang; Jian-Ping You; Qing Mao
Journal:  Virol J       Date:  2013-01-15       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.